All Articles

Journey Medical posts a stellar 23% revenue jump, nearing profitability. But beyond the headlines, a crucial SEC filing reveals a complex financial reality.

With pivotal lung cancer data imminent, ArriVent BioPharma juggles a high-risk, high-reward strategy, betting its future on a novel drug and a new wave of ‘smart bomb’ therapies.

Genomic pioneer Sangamo sells key assets to PTC and Lilly in a $163M bankruptcy deal, reshaping the future of gene therapy and rare disease treatment.

A 30% revenue dip masks a strategic pivot at OptimizeRx. Inside the numbers, a story of disciplined debt management and a bold bet on AI innovation emerges.

Two former colleagues, Ben Brown and Wayne Watson, now co-lead BOND's AV division. This reunion isn't just sentimental—it's a calculated move for market dominance.

From the TV studio to the C-suite, four leaders are redefining wellness. NYAM's 2026 gala honors the innovators building the future of health.

FGI Industries defied market chaos with a stunning return to profitability, driven by disciplined cost control and a savvy global sourcing strategy.

The private credit firm posted a strong quarter with a rising NAV, but the real story is the recent acquisition of its advisor by asset giant Ridgepost Capital.

With an October FDA deadline for its lead drug, INOVIO walks a financial tightrope, betting its future on a first-in-class treatment and a broader DNA platform.

Identiv sells its core IoT business, pivoting to a high-risk, high-reward strategy in Physical AI and Compliance SaaS. A deep dive into the deal.

SR Alternative Credit's latest deal reveals a contrarian truth: the risky world of subprime auto lending is a calculated goldmine for niche financiers.

A private group aims to raise $25M to unlock Tanzania's vast mineral wealth. Is this a new model for development or a repeat of the old extraction playbook?

Beasley Broadcast Group's massive Q2 profit stems from a debt maneuver, not revenue. A deep dive into its digital pivot and cost cuts reveals its true test.

South Korea's PharmaResearch is strategically embedding its REJURAN skin booster in Australia, moving beyond sales to reshape aesthetics with science and education.

With Visa, Wells Fargo, and Alibaba joining the Agentic AI Foundation, the race is on to build open standards for a future run by autonomous AI.

A standard 3% raise feels like a reward, but it's a rounding error. A new analysis reveals how tech workers leave millions on the table by staying put.

Red Bull's fan-powered concert isn't just a gimmick. It's a calculated play in the experience economy, betting that the future of brand loyalty is co-creation.

Omni Family of Services is now a 'Hope-Centered Organization.' But can a psychological theory really fix burnout and change outcomes for America's most vulnerable?

Samsonite's acquisition of Shay Mitchell's BÉIS isn't just about luggage; it's a masterclass in how heritage brands are buying digital savvy to navigate the future.

A new partnership model between Vitamin Angels and Indonesia's government is tackling malnutrition not just with vitamins, but with systemic upgrades to save lives.